Literature DB >> 7927251

Hereditary tyrosinemia type I: a new clinical classification with difference in prognosis on dietary treatment.

F J van Spronsen1, Y Thomasse, G P Smit, J V Leonard, P T Clayton, V Fidler, R Berger, H S Heymans.   

Abstract

Hereditary tyrosinemia type I (McKusick 27670) is a heterogeneous disease with poor prognosis, yet there are few reports of the long-term prognosis. It is therefore difficult to decide on the treatment for individual patients. We have conducted an international survey of patients with tyrosinemia type I and examined the probability of survival on dietary treatment and the causes of death in 108 patients with tyrosinemia type I. The survival after the onset of symptoms varied with the age at onset; the earlier the symptoms developed the poorer the outlook. Liver failure and recurrent bleeding (67%), hepatocellular carcinoma (17%) and the porphyria-like syndrome with respiratory failure (10%) were the most common causes of death. The 1- and 2-yr survival probability after the onset of symptoms in patients in whom symptoms developed before 2 mo, between 2 and 6 mo and after 6 mo were 38%/29%, 74%/74% and 96%/96%, respectively. On the basis of these survival rates, a new classification--which is important with respect to choices in treatment--is proposed: very early (onset of symptoms < 2 mo), early (2 to 6 mo) and late presenting form (> 6 mo).

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7927251

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  46 in total

1.  Heterogeneity of follow-up procedures in French and Belgian patients with treated hereditary tyrosinemia type 1: results of a questionnaire and proposed guidelines.

Authors:  Manuel Schiff; Pierre Broue; Brigitte Chabrol; Corinne De Laet; Dalila Habes; Karine Mention; Jacques Sarles; Anne Spraul; Vassili Valayannopoulos; Hélène Ogier de Baulny
Journal:  J Inherit Metab Dis       Date:  2011-12-14       Impact factor: 4.982

2.  Renal function in tyrosinaemia type I after liver transplantation: a long-term follow-up.

Authors:  L J W M Pierik; F J van Spronsen; C M A Bijleveld; C M L van Dael
Journal:  J Inherit Metab Dis       Date:  2005       Impact factor: 4.982

3.  Tyrosinemia type I and not treatment with NTBC causes slower learning and altered behavior in mice.

Authors:  Megan A Hillgartner; Sarah B Coker; Ashton E Koenig; Marissa E Moore; Elizabeth Barnby; Gordon G MacGregor
Journal:  J Inherit Metab Dis       Date:  2016-06-06       Impact factor: 4.982

4.  Treatment of two children with hereditary tyrosinaemia type I and long-standing renal disease with a 4-hydroxyphenylpyruvate dioxygenase inhibitor (NTBC).

Authors:  E Pronicka; E Rowinska; Z Bentkowski; J Zawadzki; E Holme; S Lindstedt
Journal:  J Inherit Metab Dis       Date:  1996       Impact factor: 4.982

5.  Mutation spectrum of fumarylacetoacetase gene and clinical aspects of tyrosinemia type I disease.

Authors:  A Dursun; R K Ozgül; S Sivri; A Tokatlı; A Güzel; L Mesci; M Kılıç; D Aliefendioglu; F Ozçay; M Gündüz; T Coşkun
Journal:  JIMD Rep       Date:  2011-06-22

6.  Tyrosinemia Typel: A case report.

Authors:  Mohmood M Rashad; Carmen Nassar
Journal:  Sudan J Paediatr       Date:  2011

7.  Outcome of tyrosinaemia type III.

Authors:  C J Ellaway; E Holme; S Standing; M A Preece; A Green; E Ploechl; M Ugarte; F K Trefz; J V Leonard
Journal:  J Inherit Metab Dis       Date:  2001-12       Impact factor: 4.982

8.  Geographical and Ethnic Distribution of Mutations of the Fumarylacetoacetate Hydrolase Gene in Hereditary Tyrosinemia Type 1.

Authors:  Francesca Angileri; Anne Bergeron; Geneviève Morrow; Francine Lettre; George Gray; Tim Hutchin; Sarah Ball; Robert M Tanguay
Journal:  JIMD Rep       Date:  2015-02-15

Review 9.  Tyrosinaemia type I and NTBC (2-(2-nitro-4-trifluoromethylbenzoyl)-1,3-cyclohexanedione).

Authors:  E Holme; S Lindstedt
Journal:  J Inherit Metab Dis       Date:  1998-08       Impact factor: 4.982

10.  Cost-Consequence Analysis of Nitisinone for Treatment of Tyrosinemia Type I.

Authors:  Mariève Simoncelli; Johanne Samson; Jean-François Bussières; Jacques Lacroix; Marc Dorais; Renaldo Battista; Sylvie Perreault
Journal:  Can J Hosp Pharm       Date:  2015 May-Jun
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.